Proteomics International Managing Director Dr Richard Lipscombe said the prototype test, named PromarkerEso, was now showing strong discrimination at early and late stages of the disease. “We’ve refined our diagnostic models to correctly identify 89% of patients with oesophageal adenocarcinoma and 92% of patients without the disease. This means we could have a simple blood test to determine who would benefit from an endoscopy. We believe that such a test would garner significant clinical and commercial interest should it be further validated.”
